SEARCH

SEARCH BY CITATION

References

  • 1
    Farrell GC, Chitturi S, Lau GKK, Sollano J, the Asia-Pacific Working Party on non-alcoholic fatty liver disease (NAFLD). Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia–Pacific region: Executive summary. J. Gastroenterol. Hepatol. 2007; 22: 7757.
  • 2
    Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99S112.
  • 3
    Farrell GC. NASH: what is it, and why is it important in the Asia-Pacific region? J. Gastroenterol. Hepatol. 2003; 18: 12438.
  • 4
    Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 122131.
  • 5
    Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 2001; 21: 2741.
  • 6
    Sanyal AJ, American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 170525.
  • 7
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 246774.
    Direct Link:
  • 8
    Hall PM, Kirsch R. Pathology of hepatic steatosis, NASH and related conditions. In: FarrellGC, HallPM, GeorgeJ, McCulloughAJ, eds. Fatty Liver Disease. NASH and Related Conditions. Malden, MA: Blackwell Publishing, 2005; 1322.
  • 9
    Kleiner DE, Brunt EM, Van Natta M et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 131321.
  • 10
    Fan JG, Saibara T, Chitturi S, Sung JJY, Kim BI, Chutaputti A, the Asia–Pacific Working Party for NAFLD. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia–Pacific? J. Gastroenterol. Hepatol. 2007; 22: 794800.
  • 11
    Fan JG, Zhu J, Li XJ et al. Fatty liver and the metabolic syndrome among Shanghai adults. J. Gastroenterol. Hepatol. 2005; 20: 182532.
  • 12
    Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 91723.
  • 13
    Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 3739.
  • 14
    Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005; 143: 7228.
  • 15
    Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 2006; 40: S510.
  • 16
    Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000; 132: 11217.
  • 17
    McCullough AJ. The epidemiology and risk factors of NASH. In: FarrellGC, HallPM, GeorgeJ, McCulloughAJ, eds. Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell Publishing, 2005; 2337.
  • 18
    Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 138795.
  • 19
    Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 110610.
  • 20
    Ratziu V, Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 2006; 44: 8025.
  • 21
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 141319.
  • 22
    Teli MR, James OFW, Burt AD, Bennet MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 6: 171419.
  • 23
    Dam-Larsen S, Franzmann M, Andersen IB et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 7505.
  • 24
    Fassio F, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 8206.
  • 25
    Hui JM, Kench JG, Chitturi S et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 4207.
  • 26
    Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 11321.
  • 27
    Hashimoto E, Yatsuji S, Kaneda H et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol. Res. 2005; 33: 726.
  • 28
    Sanyal AJ, Banas C, Sargeant C et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 6829.
  • 29
    Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 134954.
  • 30
    Ratziu V, Bonyhay L, Di Martino V et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 148593.
  • 31
    Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 13440.
  • 32
    Shimada M, Hashimoto E, Taniai M et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 2002; 37: 15460.
  • 33
    Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42: 513.
  • 34
    Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695704.
  • 35
    Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006; 43: 117786.
  • 36
    Tarantino G, Conca P, Sorrentino P, Ariello M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J. Gastroenterol. Hepatol. 2006; 21: 12668.
  • 37
    Chan HL-Y, De Silva HJ, Leung NW-Y, Lim S-G, Farrell GC, the Asia–Pacific Working Party on NAFLD. How should we manage patients with non-alcoholic fatty liver disease in 2007? J. Gastroenterol. Hepatol. 2007; 22: 8018.
  • 38
    Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J. Gastroenterol. Hepatol. 2004; 19: 36874.
  • 39
    Amarapurkar DN, Hashimoto E, Lesmana LA et al. How common is non-alcoholic fatty liver disease in the Asia–Pacific region and are there local differences? J. Gastroenterol. Hepatol. 2007; 22: 78893.
  • 40
    Kojima S-I, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J. Gastroenterol. 2003; 38: 95461.
  • 41
    Jimba S, Nakagami T, Takahashi M et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005; 22: 11415.
  • 42
    Park SH, Jeon WK, Kim SH et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J. Gastroenterol. Hepatol. 2006; 21: 13843.
  • 43
    Park SH, Kim BI, Kim HJ et al. Clinical features associated with improvement of fatty liver disease. Intern. Med. J. 2005; 35:4737.
  • 44
    Petersen KF, Dufour S, Feng J et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl. Acad. Sci. USA 2006; 103: 18277.
  • 45
    Weston SR, Leydon W, Murphy R et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41: 3729.
  • 46
    Chen QK, Chen HY, Huang KH et al. Clinical features and risk factors of patients with fatty liver in Guangzhou area. World J. Gastroenterol. 2004; 10: 899902.
  • 47
    Tsang SW, Ng WF, Wu BP, Chow DA, Li ET, Wong TC. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2006; 21: 11621.
  • 48
    Wong VW, Hui AY, Tsang SW et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006; 4: 115461.
  • 49
    Sreenivasa Baba C, Alexander G, Kalyani B et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2006; 21: 1918.
  • 50
    Duseja A, Das R, Nanda M, Das A, Garewal G, Chawla Y. Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J. Gastroenterol. 2005; 11: 3935.
  • 51
    Madan K, Batra Y, Gupta SD et al. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World J. Gastroenterol. 2006; 12: 34005.
  • 52
    Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2006; 21: 145965.
  • 53
    Malik A, Ida H, Cheah PL, Goh KL. Nonalcoholic fatty liver disease (NAFLD): a clinical, biochemical and histopathological study in Malaysian patients. J. Gastroenterol. Hepatol. 2004; 19: A835.
  • 54
    Khurram M, Umar M, Rizwan A et al. Clinical spectrum of nonalcoholic steatohepatitis in non diabetic population. J. Gastroenterol. Hepatol. 2004; 19: A833.
  • 55
    Payawal DA, Clavio JA, Alvarez SZ, Chan MM, Sollano JD. Does transaminase level predict severity of liver disease in nonalcoholic fatty liver disease? J. Gastroenterol. Hepatol. 2004; 19:A836.
  • 56
    Kim HJ, Kim HJ, Lee KE et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch. Intern. Med. 2004; 164: 216975.
  • 57
    De Hewavisenthi SJ, Dassanayaka AS, De Silva HJ. Clinical, biochemical and histological characteristics of a Sri Lankan population of non-alcoholic steatohepatitis (NASH) patients. Ceylon Med. J. 2005; 50: 11316.
  • 58
    Chen CH, Huang MH, Yang JC et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J. Clin. Gastroenterol. 2006; 40: 74552.
  • 59
    Chien KL, Hsu HC, Chao CL, Lee BC, Chen MF, Lee YT. Interaction of obesity, metabolic syndrome and Framingham risk on steatohepatitis among healthy Taiwanese: population-based nested case-control study. Cardiovasc. Diabetol. 2006; 5: 12.
  • 60
    Apiratpracha W, Dumrongpisutikul S, Apirakkhit W, Chutaputti A. Serum leptin levels in Thai patients with nonalcoholic fatty liver disease at Pramongkutklao hospital. J. Gastroenterol. Hepatol. 2004; 19: A868.
  • 61
    Oh KC, Park SH, Park JC et al. Is the prevalence of cryptogenic hepatocellular carcinoma increasing in Korea? Korean J. Gastroenterol. 2005; 45: 4551.
  • 62
    Sakugawa H, Nakasone H, Nakayoshi T et al. Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan. Hepatogastroenterology 2003; 50: 20058.
  • 63
    Kojima H, Sakurai S, Matsumura M et al. Cryptogenic cirrhosis in the region where obesity is not prevalent. World J. Gastroenterol. 2006; 12: 20805.
  • 64
    Duseja A, Nanda M, Das A, Das R, Bhansali A, Chawla Y. Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis. Trop. Gastroenterol. 2004; 25: 1517.
  • 65
    Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 6649.
  • 66
    Hui AY, Wong VW, Chan HL et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment. Pharmacol. Ther. 2005; 21: 40713.
  • 67
    Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 105962.
  • 68
    International Diabetes Federation. Criteria for Metabolic Syndrome. Cited 16 January 2007. Available from URL: http://idf.org/webdata/docs/MetSyndrome_FINAL.pdf
  • 69
    World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications—Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, 1999; 201.
  • 70
    Bravo AA, Sheth SG, Chopra S. Current concepts: liver biopsy. N. Engl. J. Med. 2001; 344: 495500.
  • 71
    Van Der Poorten D, Kwok A, Lam T et al. Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern. Med. J. 2006; 36: 6929.
  • 72
    Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898906.
  • 73
    Friedman LS. Controversies in liver biopsy: who, where, when, how, and why? Curr. Gastroenterol. Rep. 2004; 6: 306.
  • 74
    Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 74550.
  • 75
    Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J. Exp. Med. 1983; 139:4350.
  • 76
    Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 128692.
  • 77
    Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002; 137: 110.
  • 78
    Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005; 42:6506.
  • 79
    George J, Farrell GC. Practical approach to the diagnosis and management of people with fatty liver diseases. In: FarrellGC, HallP, GeorgeJ, McCulloughAJ, eds. Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell Publishing, 2005; 18193.
  • 80
    Hayashi PH, Harrison SA, Torgerson S, Perez TA, Nochajski T, Russell M. Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related. Am. J. Gastroenterol. 2004; 99: 7681.
    Direct Link:
  • 81
    Wong VW, Hui AY, Tsang SW et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2006; 24: 121522.
  • 82
    McCullough AJ. Thiazolidinediones for nonalcoholic steatohepatitis – promising but not ready for prime time. N. Engl. J. Med. 2006; 355: 23613.
  • 83
    Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 6038.
  • 84
    Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 2006; 40: S3943.
  • 85
    Wang RT, Koretz RI, Yee HF Jr. Is weight reduction an effective therapy for nonalcoholic fatty liver disease? A systematic review. Am. J. Med. 2003; 115: 5549.
  • 86
    Klein S, Mittendorfer B, Eagon JC et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006; 130: 156472.
  • 87
    Wong VW, Hui AY, Tsang SW et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2006; 24: 121522.